Searching over 5,500,000 cases.


searching
Buy This Entire Record For $7.95

Download the entire decision to receive the complete text, official citation,
docket number, dissents and concurrences, and footnotes for this case.

Learn more about what you receive with purchase of this case.

Dynport Vaccine Co. LLC v. Lonza Biologics, Inc.

United States District Court, D. Maryland

May 1, 2015

DYNPORT VACCINE CO. LLC, Plaintiff,
v.
LONZA BIOLOGICS, INC., Defendant.

MEMORANDUM

JAMES K. BREDAR, District Judge.

Plaintiff DynPort Vaccine Company LLC sued Defendant Lonza Biologics, Inc., in a three-count complaint, alleging breach of contract, negligence, and unjust enrichment. (Compl., ECF No. 1.) Pending before the Court is Lonza's motion to dismiss or, in the alternative, for more definite statement under Federal Rule of Civil Procedure 12(b)(6) and 12(e). (ECF No. 12.) The matter has been briefed (ECF Nos. 13 and 17), and no hearing is required, Local Rule 105.6 (D. Md. 2014). Treating Lonza's motion as a motion to dismiss, the Court will grant it in part and deny it in part. Treating it as a motion for more definite statement, the Court will grant the motion as to Count I.

I. Standard of Dismissal for Failure to State a Claim

A complaint must contain "sufficient factual matter, accepted as true, to state a claim to relief that is plausible on its face.'" Ashcroft v. Iqbal, 556 U.S. 662, 678 (2009) (quoting Bell Atlantic Corp. v. Twombly, 550 U.S. 544, 570 (2007)). Facial plausibility exists "when the plaintiff pleads factual content that allows the court to draw the reasonable inference that the defendant is liable for the misconduct alleged." Iqbal, 556 U.S. at 678. An inference of a mere possibility of misconduct is not sufficient to support a plausible claim. Id. at 679. As the Twombly opinion stated, "Factual allegations must be enough to raise a right to relief above the speculative level." 550 U.S. at 555. "A pleading that offers labels and conclusions' or a formulaic recitation of the elements of a cause of action will not do.'... Nor does a complaint suffice if it tenders naked assertion[s]' devoid of further factual enhancement.'" Iqbal, 556 U.S. at 678 (quoting Twombly, 550 U.S. at 555, 557). Although when considering a motion to dismiss a court must accept as true all factual allegations in the complaint, this principle does not apply to legal conclusions couched as factual allegations. Twombly, 550 U.S. at 555.

II. Standard for More Definite Statement

Under Rule 12(e),
[a] party may move for a more definite statement of a pleading to which a responsive pleading is allowed but which is so vague or ambiguous that the party cannot reasonably prepare a response. The motion must... point out the defects complained of and the details desired.

Noting the interplay between the fundamental pleading requirements of Rule 8(a) and the permissibility of a motion for more definite statement under Rule 12(e), the Fourth Circuit has stated, "when the complaint conforms to Rule 8(a) and it is neither so vague nor so ambiguous that the defendant cannot reasonably be required to answer, the district court should deny a motion for a more definite statement." Hodgson v. Va. Baptist Hosp., 482 F.2d 821, 824 (4th Cir. 1973).

III. Allegations of the Complaint

DynPort alleges it has a contract with the United States government to develop a vaccine against botulinum neurotoxin for the U.S. military and that DynPort, in turn, contracted with Lonza to manufacture the vaccine for DynPort. (Compl. ¶ 1.) DynPort alleges it entered into a basic ordering agreement ("BOA") in 2002 with Lonza, [1] wherein Lonza "agreed to provide certain services, pursuant to task orders, in the development of certain vaccine products." ( Id. ¶ 9.) DynPort issued various task orders ("TOs") to Lonza, including three mentioned specifically in the complaint: TO 24 (January 2008), TO 32 (December 2010), and TO 29 (June 2011). ( Id. ¶¶ 16, 18, 19.) Under these three TOs, DynPort paid Lonza $18.9 million for work to be performed. ( Id. ¶ 22.)

In early February 2013, DynPort learned that Lonza's work on the TOs had to be delayed because Lonza's Hopkinton, Massachusetts, facility was required by the Food & Drug Administration ("FDA") to implement certain corrective actions to address the FDA's criticisms of Lonza's manufacturing practices. ( Id. ¶ 23.) On July 25, 2013, a press release from Lonza announced it was moving its Hopkinton operations to a facility in Visp, Switzerland. ( Id. ¶ 24.) The same day, DynPort advised Lonza via letter of DynPort's concern as to "the impact of these events on Lonza's ability to comply with its production requirements under the pending task orders, and requested that Lonza provide a cure plan to ensure that the schedule would be maintained and that the outstanding task orders would be timely completed." ( Id. ¶ 25.) Concurrently, DynPort warned Lonza that its failure to comply might result in DynPort's termination of the BOA for default. ( Id. )

In a letter dated August 5, 2013, Lonza indicated that its decision about Hopkinton "would not further impact [DynPort], and that Lonza was willing to transfer the ongoing work to its facility in Visp, Switzerland, at cost to [DynPort]. Lonza did not provide a cure plan." ( Id. ¶ 26.) Three days later, DynPort wrote Lonza, pointing out the deficiency in Lonza's response and directing "Lonza to commence the Antigen B Process Performance Qualification (PPQ) campaign at the Lonza Hopkinton facility no later than September 23, 2013 under the terms of the referenced subcontract or Lonza will be considered to be in breach of its subcontract." ( Id. ¶ 27.) Further, in a letter dated August 12, 2013, DynPort demanded Lonza provide no later than August 19, 2013, its written confirmation of Lonza's concurrence with DynPort's requested start date of September 23, 2013, at the Hopkinton facility. ( Id. ¶ 30.) In an August 19, 2013, letter, DynPort warned Lonza that its failure to comply with this direction from DynPort would be considered a breach of the subcontract, that DynPort would file a claim for damages against Lonza, and that DynPort would hold Lonza liable for all technology transfer costs to another manufacturing facility. ( Id. ¶ 32.) Not receiving a response from Lonza within the allotted time, DynPort "by letter dated August 23, 2013, notified Lonza that it was in breach of contract and that, under the terms of the BOA and the Federal Acquisition Regulations, [DynPort] would proceed with termination efforts on all open Task Orders." ( Id. ¶ 33.)

In a letter dated September 5, 2013, Lonza acknowledged DynPort's termination of the contract and pledged to cooperate in the transfer of technology and intellectual property to another manufacturer. ( Id. ¶ 34.) This pledge was broken when Lonza thereafter refused to transfer the technology and intellectual property to DynPort until they had reached a final resolution of the issues of liability and damages. ( Id. ¶ 35.) After DynPort filed suit for injunctive relief on the issue of transfer of technology and intellectual property, DynPort Vaccine Co., Inc. v. Lonza Biologics, Inc., Civ. No. JKB-13-3291 (D. Md.), the parties resolved that issue and DynPort voluntarily dismissed its suit without prejudice. ( Id. ¶ 35.)

DynPort alleges it has incurred significant costs because of Lonza's refusal to perform and its breach of the agreement, including "retention of a new manufacturer, transfer of the production to that new manufacturer, manufacturing of new conformance lots for the Phase 3 clinical trial, and implementation costs incurred for the Phase 3 clinical trial." ( Id. ¶ 36.) Additionally, DynPort alleges that a consequence of Lonza's failure to perform is that "major elements of the vaccine development process must be redone"; ...


Buy This Entire Record For $7.95

Download the entire decision to receive the complete text, official citation,
docket number, dissents and concurrences, and footnotes for this case.

Learn more about what you receive with purchase of this case.